EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC 4.0

Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative

Christie Rampersad iD, William Kong, Chris Wiebe iD, Robert Balshaw, Jared Bullard, Armelle Perez Cortes Villalobos, Aaron Trachtenberg iD, James Shaw, Martin Karpinski, Peter W Nickerson iD, Julie Ho iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15292 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Christie Rampersad and 10 co-authors. Institution: University Health Network, University of Toronto, Toronto, Ontario, Canada. Major MEDLINE topics: Kidney Transplantation, Epstein-Barr Virus Infections, BK Virus, Cytomegalovirus Infections. Cited 3 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: CIHR, Canadian Institutes of Health Research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

There is variability in recommended viral monitoring protocols after kidney transplant. In response to increased demand for laboratory testing during the COVID‐19 pandemic, the Transplant Manitoba Adult Kidney Program updated its monitoring protocols for cytomegalovirus (CMV), Epstein‐Barr virus (EBV), and BK polyomavirus (BKV) to a reduced frequency.

Methods

This single‐center nested case‐control study evaluated 252 adult kidney transplant recipients transplanted from 2015 to 2021, with the updated protocols effective on March 19 th 2020. Cases included recipients transplanted after the protocol update who developed CMV, EBV, and BKV DNAemia and were matched to controls with DNAemia transplanted prior to the protocol update. The primary outcome was the difference in maximum DNA load titers between cases and matched controls. Secondary outcomes included time to initial DNAemia detection and DNAemia clearance. Safety outcomes of tissue‐invasive viral disease were described.

Results

There were 216 recipients transplanted preupdate and 36 recipients postupdate. There was no difference between cases and controls in maximum or first DNA load titers for EBV, CMV, or BKV. Cases experienced earlier EBV DNAemia detection (26 (IQR 8, 32) vs. 434 (IQR 96, 1184) days, p = .005). Median follow‐up was significantly longer for recipients transplanted preupdate (4.3 vs. 1.3 years, p < .0001). After adjusting for follow‐up time, there was no difference in DNAemia clearance or tissue‐invasive viral disease.

Conclusion

Our findings suggest that reduced frequency viral monitoring protocols may be safe and cost‐effective. This quality assurance initiative should be extended to detect longer‐term and tissue‐invasive disease outcomes.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationEpstein-Barr Virus InfectionsBK VirusCytomegalovirus InfectionsAdultHumansHerpesvirus 4, HumanCytomegalovirusCase-Control StudiesPandemicsDNADNA, ViralTransplant Recipients

Author keywords

BK polyomavirusEpstein‐Barr viruscytomegaloviruskidney transplant

Substances

DNADNA, Viral

Authors and institutions

  • University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Transplant Manitoba Adult Kidney Program, Winnipeg, Manitoba, Canada.
  • George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada.
  • Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.
  • Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID profiles: Christie Rampersad, Chris Wiebe, Aaron Trachtenberg, Peter W Nickerson, Julie Ho

Funding

  • CIHR
  • Canadian Institutes of Health Research

Cite

APA

Rampersad, C., Kong, W., Wiebe, C., Balshaw, R., Bullard, J., Villalobos, A. P. C., Trachtenberg, A., Shaw, J., Karpinski, M., Nickerson, P. W., & Ho, J. (2024). Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative. Clinical Transplantation. https://doi.org/10.1111/ctr.15292

Vancouver

Rampersad C, Kong W, Wiebe C, Balshaw R, Bullard J, Villalobos APC, et al. Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative. Clinical Transplantation. 2024. doi:10.1111/ctr.15292

BibTeX
@article{Rampersad2024,
  author = {Rampersad, Christie and Kong, William and Wiebe, Chris and Balshaw, Robert and Bullard, Jared and Villalobos, Armelle Perez Cortes and Trachtenberg, Aaron and Shaw, James and Karpinski, Martin and Nickerson, Peter W and Ho, Julie},
  title = {Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15292}
}
Start for free →